KMT2D and acute myeloid leukemia: KMT2D deficiency reduced H3K4 methylation levels and suppressed the expression of DDIT4, the negative regulator in the mTOR signaling pathway, which led to the activation of the mTOR pathway and enhancement of ribosome biogenesis, thus contributing to AML development (Figure 6G).